Health Canada approves use of Moderna vaccine for children as young as 12
Advertisement
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Monthly Digital Subscription
$1 per week for 24 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Billed as $4.00 plus GST every four weeks. After 24 weeks, price increases to the regular rate of $19.00 plus GST every four weeks. Offer available to new and qualified returning subscribers only. Cancel any time.
Monthly Digital Subscription
$4.75/week*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Billed as $19 plus GST every four weeks. Cancel any time.
To continue reading, please subscribe:
Add Free Press access to your Brandon Sun subscription for only an additional
$1 for the first 4 weeks*
*Your next subscription payment will increase by $1.00 and you will be charged $16.99 plus GST for four weeks. After four weeks, your payment will increase to $23.99 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
Hey there, time traveller!
This article was published 27/08/2021 (1520 days ago), so information in it may no longer be current.
Health Canada announced Friday it has authorized the Moderna vaccine for children as young as 12 to help in the fight against COVID-19.
This is the second vaccine available in Canada to children 12 to 17 years old. Pfizer received regulatory approval for use in children as young as 12 in May of this year.
The decision comes just weeks before children across the province go in-class learning. “The ongoing COVID-19 pandemic has a significant impact on public health. The availability of safe and effective vaccines helps reduce the spread and severity of COVID-19 disease and reduce its social and economic consequences,” the federal health agency said,
The agency reports that a total of 3,732 adolescents between the ages of 12 and 17 were enrolled in the study and randomly received either two doses of the vaccine or placebo 28 days apart.
“Participants with known history of SARS-CoV-2 infection were excluded from the study. All participants will be followed for the assessment of safety, efficacy and immunogenicity for up to 1 year after Dose 2 of the vaccination,” the agency reported.
Health Canada says that the most common adverse reactions for the group that received the vaccine was pain or swelling at the injection site, fatigue and headaches, and that reactions, if any, typically lasted one to three days.
“The vaccine efficacy demonstrated in adolescents 12 to 17 years of age is consistent with the VE previously demonstrated in the adult population,” the health agency concluded.
Ivy Mak is a team editor on the Star’s breaking news desk, based in Toronto. Reach her via email: ivymak@thestar.ca
Related Articles
Pfizer seeking FDA OK for COVID-19 vaccine booster dose
Advertisement Advertise With Us